An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2019
At a glance
- Drugs Evinacumab (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Registrational
- Sponsors Regeneron Pharmaceuticals
- 06 Oct 2018 Planned number of patients changed from 70 to 100.
- 31 Aug 2018 Biomarkers information updated
- 02 May 2018 Planned End Date changed from 6 Oct 2022 to 1 Apr 2022.